How Common Is It to Be a Carrier of Smith-Lemli-Opitz Syndrome?

Among people of European descent, roughly one in every 30 to 50 individuals carries a single faulty copy of the gene behind Smith-Lemli-Opitz syndrome (SLOS), making it one of the more common recessive carrier states in that population. The exact number depends on ancestry, with some groups showing carrier rates as high as one in 43. That frequency is surprisingly high for a condition most people have never heard of, and the mismatch between how many carriers exist and how many affected babies are actually born raises its own set of questions.

Carrier Rates Vary Sharply by Ancestry

SLOS is caused by mutations in the DHCR7 gene, and carrier frequency differs substantially across ethnic groups. The highest documented rates are in Ashkenazi Jewish and Northern European populations. A study analyzing carrier frequencies across multiple populations found the rate was about one in 43 among Ashkenazi Jews and one in 54 among Northern Europeans.¹ Separate screening studies looking at the most common SLOS-causing mutation in Caucasian Americans estimated an overall carrier frequency for all DHCR7 mutations as high as one in 30.² A similar one-in-30 estimate was calculated for European Caucasians in a separate study that also, for the first time, found the mutation in individuals of African ancestry.³

At the other end of the spectrum, SLOS is extremely rare in East Asian and Finnish populations. A PCR-based screening study found the most common SLOS mutation in one of 90 Caucasian Americans but detected it in none of the 121 Africans from Sierra Leone, 120 Finns, 95 Chinese, or 103 Japanese individuals tested.⁴ A large European analysis of nearly 8,000 gene copies confirmed these geographic patterns: common mutations reached their highest frequency in Northwestern Europe, while Southern European populations carried a different set of mutations at much lower rates, and SLOS was virtually absent from Finland.⁵

The upshot is that if you are of Northern European or Ashkenazi Jewish background, you have roughly a two to three percent chance of carrying one SLOS mutation without knowing it. If you are of East Asian, Finnish, or most African backgrounds, the probability is far lower and possibly close to zero for the most common mutations, though rarer variants could still appear.

Why So Many Carriers but So Few Diagnosed Cases

Here is where the numbers get puzzling. If one in 30 Caucasians carries an SLOS mutation, you would expect the syndrome to appear in roughly one in every 1,600 to 3,600 births in that population, depending on how the math is done. Yet clinical diagnoses are far rarer than that, typically estimated at one in 20,000 to 60,000 births. Something is clearly filling the gap.

The most likely explanation is that many affected pregnancies never make it to term. A case report reviewing the carrier frequency literature noted that the expected prevalence of SLOS, based on known carrier rates, should be significantly higher than what doctors actually observe, and pointed to increased pregnancy loss in affected embryos as the probable reason.⁶ The study that originally estimated a one-in-30 carrier frequency explicitly noted that the current incidence estimate may significantly underestimate the true occurrence of SLOS.²

A Polish study that compared newborn screening predictions with actual clinical diagnoses found a striking mismatch, too. The researchers considered three possibilities: that SLOS carriers have reduced fertility, that affected fetuses die before birth, or that the condition is simply underdiagnosed after birth. They concluded that underdiagnosis in living children may play a larger role than previously assumed, because their data did not strongly support the fertility or fetal-loss explanations alone.⁷ In reality, the gap probably results from a combination of all three: some pregnancies end early, some mildly affected children are never diagnosed, and the interplay between these factors makes the true birth prevalence hard to pin down.

Supporting the prenatal loss hypothesis, studies of pregnant women with low unconjugated estriol on routine screening, a marker that can flag SLOS, have found high rates of fetal death. In one study, fetal death occurred in over half of such pregnancies when other screening markers were also abnormal.⁸ This fits with the biology of the condition: cholesterol is critical for fetal development, and severely affected embryos may simply not survive.

What the Gene Actually Does

DHCR7 encodes an enzyme that performs the final step in one of the body’s cholesterol-manufacturing pathways. It converts a precursor molecule called 7-dehydrocholesterol (7-DHC) into cholesterol.⁹ When both copies of the gene are broken, as in a person with SLOS, that conversion stalls. The result is a buildup of 7-DHC and a shortage of cholesterol, which derails the normal development of the brain, limbs, and internal organs.¹⁰

Carriers, who have one working copy and one faulty copy, produce enough of the enzyme to make adequate cholesterol for their own needs. They do not develop SLOS or show obvious clinical symptoms. But the enzyme’s position at the crossroads between cholesterol production and vitamin D synthesis makes it biologically interesting even in people who carry just one mutation, as discussed below.

An Evolutionary Reason the Carrier Rate Is So High

One in 30 is a remarkably common carrier rate for a potentially lethal recessive disorder. Geneticists have wondered whether carrying one SLOS mutation might confer a survival advantage, similar to how carrying one sickle-cell gene offers partial protection against malaria.

A compelling hypothesis centers on vitamin D. The same molecule that DHCR7 converts into cholesterol, 7-DHC, is also the precursor that skin cells use to make vitamin D when exposed to sunlight. Having slightly less DHCR7 activity could, in theory, leave more 7-DHC available for vitamin D production, a meaningful advantage at northern latitudes where sunlight is scarce. An evolutionary analysis found strong evidence of positive selection for DHCR7 variants in northern populations. Extended stretches of DNA around the gene showed patterns consistent with a recent selective sweep, and the relevant gene variants were highly prevalent in Europe, present on about 72 percent of chromosomes, compared with 41 percent in Northeast Asia.¹¹

If this hypothesis is correct, the high carrier frequency in Northern Europeans and Ashkenazi Jews is not a quirk of random genetic drift. It was actively favored by natural selection because a slight reduction in DHCR7 activity boosted vitamin D levels just enough to matter for survival in UV-poor environments. The trade-off is that when two carriers have a child together, there is a one-in-four chance the child inherits both faulty copies and develops SLOS.

Different Mutations in Different Regions

Not all SLOS carriers share the same mutation. The DHCR7 gene can break in many different ways, and the particular mutations that dominate vary by geography. The most common mutation in the United States and Northwestern Europe is called IVS8-1G>C (sometimes written c.964-1G>C). It accounts for over 60 percent of SLOS cases in US patients.⁴

In Northeastern Europe, different mutations predominate. The large European study that analyzed nearly 8,000 gene copies confirmed that the mutational landscape differed significantly between populations, with frequency peaks of distinct common mutations appearing in Northwestern, Northeastern, and Southern Europe.⁵ In Czech and Hungarian populations, for example, a variant called c.452G>A was the most prevalent, accounting for about 1.8 percent of all detected gene copies in those cohorts.¹²

This geographic variation matters for screening. A test that only looks for the IVS8-1G>C mutation will catch most carriers in the US and UK but miss many in Southern or Eastern Europe. Comprehensive carrier screening panels now sequence the entire DHCR7 gene or check for a broad panel of known variants, which improves detection across populations.

How Carriers Are Identified Today

Most people who learn they are SLOS carriers find out through expanded carrier screening, a genetic test offered before or during pregnancy that checks for dozens or even hundreds of recessive conditions at once. SLOS is included on many of these panels because the carrier frequency is high enough in European-descent populations to make screening cost-effective.

An analysis of a 176-condition expanded carrier screen found the approach to be cost-effective near the commonly used benchmark of $50,000 per life-year, particularly when the savings from avoiding severe disease were factored in.¹³ A separate multi-center study in China evaluating expanded carrier screening panels also found favorable cost-effectiveness for large gene panels when used before or during pregnancy.¹⁴

SLOS can also be flagged during pregnancy through routine second-trimester blood screening. Unusually low levels of unconjugated estriol, one of the hormones measured in standard maternal serum screens, can signal a cholesterol synthesis problem in the fetus. When this marker is low, further testing with ultrasound and biochemical analysis of the amniotic fluid may be recommended.¹⁵ Low estriol alone is not specific to SLOS and can also indicate other conditions, so it is a flag rather than a diagnosis.

What It Means for a Couple When Both Partners Are Carriers

Because SLOS is autosomal recessive, a carrier has no symptoms and faces no personal health risk from the mutation. The scenario that matters is when two carriers have children together. Each pregnancy in that pairing carries a one-in-four chance of producing a child with SLOS, a one-in-two chance of producing another carrier, and a one-in-four chance of a child with no SLOS mutations at all.¹⁵

Given the carrier frequency of roughly one in 30 to one in 50 among Northern Europeans, the chance that both partners in a random pairing from that population are carriers falls somewhere between about one in 900 and one in 2,500. That is uncommon but far from negligible, and it is the primary reason genetic counselors recommend expanded carrier screening before conception when feasible. Identifying carrier couples early gives them time to explore options such as preimplantation genetic testing during IVF, prenatal diagnosis, or simply being prepared for the possibility.

The Emotional Side of Carrier Results

Learning that you carry a gene for a serious condition, even one that poses no health risk to you personally, can be unsettling. A review of the psychosocial literature on carrier testing found that common reactions include anxiety, guilt, effects on self-image, and changes in family dynamics.¹⁶ People who already have a child affected by the condition are especially likely to experience guilt and to alter their reproductive plans. Some carriers also mistakenly worry that they themselves might develop symptoms of the disorder they carry, which underscores the importance of clear genetic counseling.

A subtler finding from that same review: genetic counselors sometimes assume that parents who already have an affected child understand their own carrier status without being told explicitly, and this assumption can lead to inadequate support. If you receive a carrier result and feel confused or anxious about what it means, those feelings are normal and worth discussing with a counselor.

Do Carriers Show Any Subtle Biological Differences

In everyday life, SLOS carriers appear clinically identical to non-carriers. They make enough cholesterol, they develop normally, and standard blood tests do not flag anything unusual. But at a finer biological level, carrying one faulty DHCR7 copy may not be entirely silent.

Mouse models offer some clues. Mice engineered to carry one functional and one disrupted copy of Dhcr7, roughly equivalent to human carriers, showed no differences from normal mice on basic measures of movement, anxiety, or muscle function. However, older female carrier mice were significantly more likely to win in social dominance tests, and carrier mice of both sexes showed increased sensitivity of a specific serotonin receptor (5-HT2A) starting around six months of age.¹⁷ These are laboratory findings in mice and do not translate directly to human health, but they hint that carrying one DHCR7 mutation could subtly influence brain chemistry. Whether this has any practical relevance for the millions of human carriers walking around is an open question that researchers are still exploring.

The evolutionary evidence discussed earlier also suggests a possible functional consequence: slightly more 7-DHC available for vitamin D production. If carriers have marginally higher vitamin D synthesis in low-sunlight conditions, that would be an advantage, not a problem. It might even partly explain why the carrier rate stayed so high in Northern European populations for thousands of years despite the severe consequences of inheriting two copies.